Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Verrica Pharmaceuticals to announce earnings of ($0.41) per share and revenue of $5.7330 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The business had revenue of $5.02 million during the quarter, compared to the consensus estimate of $4.51 million. Verrica Pharmaceuticals had a negative return on equity of 1,077.78% and a negative net margin of 47.97%. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $5.41 on Wednesday. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82. The firm has a market capitalization of $92.94 million, a P/E ratio of -5.25 and a beta of 1.49. The company has a current ratio of 2.10, a quick ratio of 1.98 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $5.83 and a two-hundred day simple moving average of $6.09.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright started coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen cut shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.50.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Man Group plc purchased a new position in Verrica Pharmaceuticals in the fourth quarter worth about $94,000. Quadrature Capital Ltd purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter valued at approximately $99,000. Beck Mack & Oliver LLC bought a new stake in shares of Verrica Pharmaceuticals during the fourth quarter valued at approximately $100,000. Bridgeway Capital Management LLC bought a new stake in shares of Verrica Pharmaceuticals during the third quarter valued at approximately $52,000. Finally, XTX Topco Ltd purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $122,000. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.